157 related articles for article (PubMed ID: 22971749)
1. The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal.
Fukazawa H; Masumi A
Biol Pharm Bull; 2012; 35(11):2064-8. PubMed ID: 22971749
[TBL] [Abstract][Full Text] [Related]
2. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
[TBL] [Abstract][Full Text] [Related]
3. Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.
Crowe BL; Larue RC; Yuan C; Hess S; Kvaratskhelia M; Foster MP
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2086-91. PubMed ID: 26858406
[TBL] [Abstract][Full Text] [Related]
4. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
6. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4.
Lin YJ; Umehara T; Inoue M; Saito K; Kigawa T; Jang MK; Ozato K; Yokoyama S; Padmanabhan B; Güntert P
Protein Sci; 2008 Dec; 17(12):2174-9. PubMed ID: 18815416
[TBL] [Abstract][Full Text] [Related]
8. Identification of unique, differentiation stage-specific patterns of expression of the bromodomain-containing genes Brd2, Brd3, Brd4, and Brdt in the mouse testis.
Shang E; Salazar G; Crowley TE; Wang X; Lopez RA; Wang X; Wolgemuth DJ
Gene Expr Patterns; 2004 Sep; 4(5):513-9. PubMed ID: 15261828
[TBL] [Abstract][Full Text] [Related]
9. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
10. The Role of Bromodomain and Extraterminal Motif (BET) Proteins in Chromatin Structure.
Hsu SC; Blobel GA
Cold Spring Harb Symp Quant Biol; 2017; 82():37-43. PubMed ID: 29196562
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
12. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
14. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
15. Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration.
Gupta SS; Maetzig T; Maertens GN; Sharif A; Rothe M; Weidner-Glunde M; Galla M; Schambach A; Cherepanov P; Schulz TF
J Virol; 2013 Dec; 87(23):12721-36. PubMed ID: 24049186
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibitors: a patent review.
Garnier JM; Sharp PP; Burns CJ
Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
[TBL] [Abstract][Full Text] [Related]
17. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.
Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y
Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
[TBL] [Abstract][Full Text] [Related]
19. The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation.
Shang E; Nickerson HD; Wen D; Wang X; Wolgemuth DJ
Development; 2007 Oct; 134(19):3507-15. PubMed ID: 17728347
[TBL] [Abstract][Full Text] [Related]
20. Bromodomains as therapeutic targets in cancer.
Barbieri I; Cannizzaro E; Dawson MA
Brief Funct Genomics; 2013 May; 12(3):219-30. PubMed ID: 23543289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
